Business context and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2017—not a filing for Bio Green Med Solution, Inc. The company is a clinical-stage biopharmaceutical developer focused on cancer therapies. Its programs include CYC065, sapacitabine with seliciclib, and the Phase 3 SEAMLESS study in acute myeloid leukemia (AML), whose data analysis and site closures were ongoing.
Financial results and liquidity
| Metric (US$ millions, except per-share data) | Q1 2016 | Q1 2017 |
|---|---|---|
| Revenue | 0.139 | 0 |
| Research and development expense | 2.499 | 1.312 |
| General and administrative expense | 1.384 | 1.381 |
| Operating loss | (3.744) | (2.693) |
| Net loss | (3.041) | (1.555) |
| Net loss attributable to common stockholders | (3.091) | (1.605) |
| Basic and diluted loss per share | (1.04) | (0.38) |
| Cash used in operating activities | (3.147) | (3.810) |
Cash and cash equivalents were $12.729 million at March 31, 2017, down from $16.520 million at December 31, 2016. Working capital was $12.906 million; total liabilities were $4.255 million. The filing reports no borrowings or funded debt. Current assets were $17.034 million and current liabilities $4.128 million. Operating cash use exceeded the prior-year quarter, primarily due to working-capital changes. No meaningful revenue margin is available because Q1 2017 revenue was zero.
Material changes versus the prior comparable period
- Revenue fell from $139,000 to zero after grant revenue ended.
- R&D expense declined 48% to $1.312 million, mainly because SEAMLESS trial site closures reduced sapacitabine costs. G&A remained roughly flat at $1.381 million.
- Operating loss narrowed to $2.693 million. Net loss also narrowed, helped by $879,000 of other income associated with the Life Technologies asset purchase agreement (APA); the company recognized a related receivable.
- Other income rose to $832,000 from $210,000, while foreign exchange results shifted from a $180,000 gain to a $59,000 loss. The income tax benefit declined to $306,000 from $493,000.
- Common shares outstanding increased to 4,272,947 at March 31 from 4,256,829 at year-end. The company sold 16,118 shares under its at-the-market agreement for approximately $86,000 net proceeds in the quarter; it sold a further 167,000 shares for approximately $1.0 million net in April.
Outlook, risks, and unusual items
Management said March 31 cash, together with expected cash flows including UK R&D tax credits and recent financing, was expected to fund planned operations and capital needs through the end of 2018. Management also stated that substantial additional capital would be needed to advance development and commercialization, and that funding beyond 2018 depended on raising capital. Funding may not be available on acceptable terms or at all; potential responses include reducing or delaying programs, partnering, or limiting operations.
Management expected 2017 R&D spending to decrease as SEAMLESS sites close and G&A to remain relatively flat versus 2016. Future SEAMLESS spending and any regulatory submissions depend on final clinical data. The company anticipated continued operating losses and no significant product revenue before a candidate is approved and commercialized. It reported no material changes to the risk factors in its 2016 Form 10-K and no legal proceedings.
Notable items and exposures include the non-recurring or uncertain timing of APA income, reliance on UK R&D tax credits and equity-market financing, regulatory and clinical-development uncertainty, and potential Daiichi Sankyo milestone payments of up to $10.0 million subject to contractual milestones. Preferred stock carried a 6% cumulative dividend; a quarterly dividend was paid May 1, 2017. Management stated it did not identify conditions raising substantial doubt about the company’s ability to continue as a going concern for at least one year from issuance.
Important facts for investors to verify
- Confirm the filing identity: the source is Cyclacel Pharmaceuticals, Inc., despite the request naming Bio Green Med Solution, Inc.
- Review cash burn and runway assumptions, including the stated funding horizon through 2018 and the need for capital thereafter.
- Assess final SEAMLESS results, remaining trial-closeout costs, and whether any regulatory submissions are planned.
- Verify the nature, collectability, and timing of the $879,000 APA-related income and receivable, which depend on activity outside Cyclacel’s control.
- Track equity issuance and dilution, preferred dividends, R&D tax-credit receipts, and any contractual development milestones.